About this trial
The purpose of this study is to investigate if Cemiplimab is better than placebo when a CSCC patient has been treated after they have had both surgery and radiotherapy. This is a Phase 3 trial. It is planned that the study’s primary completion date will be 16 OCT 2023, follow-up activities will continue until 11 FEB 2026.
Patient Profile
Adults aged 18 years and older, ECOG Performance status score ≤1
Where’s this trial being run?
Cork University Hospital and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | R2810-ONC-1788 |
|---|---|
| Number: | 18-50 |
| Full Title: | A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma |
| Principal Investigator: | Dr Derek Power |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Regeneron Pharmaceuticals |
| Recruitment Started: |
Global: 31 JUL 2019 Ireland: 24 JAN 2020 |
| Global Recruitment Target: | 412 |
|---|---|
| Ireland Recruitment Target: | 8 |